购物车
  • TargetMol
    您的购物车当前为空
前往下单页继续购物
顶部相关产品产品介绍化学信息储存和溶解信息计算器

(±)19(20)-EDP Ethanolamide

货号 T35468Cas号 2123485-34-5 一键复制产品信息
Rating icon 还可以

(±)19(20)-EDP ethanolamide is an ω-3 endocannabinoid epoxide and cannabinoid (CB) receptor agonist (EC50s = 108 and 280 nM for CB1 and CB2, respectively). It is produced through direct epoxygenation of docosahexaenoyl ethanolamide by cytochrome P450 (CYP) epoxygenases. (±)19(20)-EDP ethanolamide (25 μM) reduces the viability of 143B metastatic osteosarcoma cells. It decreases the production of IL-6 and increases the production of IL-10 when used at concentrations ranging from 2.5 to 10 μM in BV-2 microglia stimulated by LPS and decreases LPS-induced cytotoxicity when used at concentrations ranging from 5 to 10 μM. It also decreases nitrite production when used at a concentration of 7.5 μM, an effect that can be partially reversed by the CB2 receptor antagonist AM630 and the PPARγ antagonist GW 9662 . (±)19(20)-EDP ethanolamide induces vasodilation of isolated preconstricted bovine coronary arteries (ED50 = 1.9 μM) and reduces tube formation by human microvascular endothelial cells (HMVECs) in a Matrigel assay.

(±)19(20)-EDP Ethanolamide

一键复制产品信息
Rating icon 还可以
货号 T35468Cas号 2123485-34-5

(±)19(20)-EDP ethanolamide is an ω-3 endocannabinoid epoxide and cannabinoid (CB) receptor agonist (EC50s = 108 and 280 nM for CB1 and CB2, respectively). It is produced through direct epoxygenation of docosahexaenoyl ethanolamide by cytochrome P450 (CYP) epoxygenases. (±)19(20)-EDP ethanolamide (25 μM) reduces the viability of 143B metastatic osteosarcoma cells. It decreases the production of IL-6 and increases the production of IL-10 when used at concentrations ranging from 2.5 to 10 μM in BV-2 microglia stimulated by LPS and decreases LPS-induced cytotoxicity when used at concentrations ranging from 5 to 10 μM. It also decreases nitrite production when used at a concentration of 7.5 μM, an effect that can be partially reversed by the CB2 receptor antagonist AM630 and the PPARγ antagonist GW 9662 . (±)19(20)-EDP ethanolamide induces vasodilation of isolated preconstricted bovine coronary arteries (ED50 = 1.9 μM) and reduces tube formation by human microvascular endothelial cells (HMVECs) in a Matrigel assay.

(±)19(20)-EDP Ethanolamide
其他形式的 “(±)19(20)-EDP Ethanolamide”:
(±)10(11)-EDP EthanolamideT354082123484-71-7
待询
规格价格库存数量
25 μg
¥ 987
35日内发货
50 μg
¥ 1,970
35日内发货
100 μg
¥ 3,660
35日内发货
500 μg
¥ 16,200
35日内发货
库存状态实时更新，以官网显示为准，现货产品可直接加购物车下单
大包装 & 定制
加入购物车

TargetMol的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

实验操作小课堂
常见问题解答
查看更多
资源下载:产品操作手册

产品介绍

生物活性
产品描述
(±)19(20)-EDP ethanolamide is an ω-3 endocannabinoid epoxide and cannabinoid (CB) receptor agonist (EC50s = 108 and 280 nM for CB1 and CB2, respectively). It is produced through direct epoxygenation of docosahexaenoyl ethanolamide by cytochrome P450 (CYP) epoxygenases. (±)19(20)-EDP ethanolamide (25 μM) reduces the viability of 143B metastatic osteosarcoma cells. It decreases the production of IL-6 and increases the production of IL-10 when used at concentrations ranging from 2.5 to 10 μM in BV-2 microglia stimulated by LPS and decreases LPS-induced cytotoxicity when used at concentrations ranging from 5 to 10 μM. It also decreases nitrite production when used at a concentration of 7.5 μM, an effect that can be partially reversed by the CB2 receptor antagonist AM630 and the PPARγ antagonist GW 9662 . (±)19(20)-EDP ethanolamide induces vasodilation of isolated preconstricted bovine coronary arteries (ED50 = 1.9 μM) and reduces tube formation by human microvascular endothelial cells (HMVECs) in a Matrigel assay.
化学信息
分子量387.564
分子式C24H37NO3
CAS No.2123485-34-5
SmilesCCC1OC1C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)NCCO
储存&溶解度
存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

实际储存温度请以COA为准

溶解度信息
DMF: 50 mg/mL (129.01 mM), Sonication is recommended.
Ethanol:PBS(pH 7.2) (1:1): 0.5 mg/mL (1.29 mM), Sonication is recommended.
DMSO: 50 mg/mL (129.01 mM), Sonication is recommended.
Ethanol: 50 mg/mL (129.01 mM), Sonication is recommended.
溶液配制表
1mg5mg10mg50mg
1 mM2.5802 mL12.9011 mL25.8022 mL129.0110 mL
DMF/DMSO/Ethanol
1mg5mg10mg50mg
5 mM0.5160 mL2.5802 mL5.1604 mL25.8022 mL
10 mM0.2580 mL1.2901 mL2.5802 mL12.9011 mL
20 mM0.1290 mL0.6451 mL1.2901 mL6.4505 mL
50 mM0.0516 mL0.2580 mL0.5160 mL2.5802 mL
100 mM0.0258 mL0.1290 mL0.2580 mL1.2901 mL
该溶液配制表仅适用于固体产品。对于液体产品，请根据标明的浓度或密度计算稀释方案。

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算，可以得到母液配置方法和体内配方的制备方法：
比如您的给药剂量是10 mg/kg，每只动物体重20 g，给药体积100 μL， 一共给药动物10只，您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O， 那么您的工作液浓度为2 mg/mL。
母液配置方法：2 mg 药物溶于 100 μL DMSO （ 母液浓度为 20 mg/mL ）, 如您需要配置的浓度超过该产品的溶解度，请先与我们联系。
体内配方的制备方法： 取 100 μL DMSO 母液， 添加 400 μL PEG300 混匀澄清， 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例，并不是具体某个化合物的推荐配制方式，请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如： DMSO， PEG300， PEG400， Tween 80， SBE-β-CD， 玉米油等， 均可在TargetMol网站点击购买。
1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成，不同的产品配方组成不同，如有配方需求，可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

剂量转换

对于不同动物的给药剂量换算，您也可以参考 更多

关键词

19(20)-EDP Ethanolamide(±)19(20)EDP Ethanolamide(±)19(20) EDP Ethanolamide
Related Tags: buy (±)19(20)-EDP Ethanolamide | purchase (±)19(20)-EDP Ethanolamide | (±)19(20)-EDP Ethanolamide cost | order (±)19(20)-EDP Ethanolamide | (±)19(20)-EDP Ethanolamide chemical structure | (±)19(20)-EDP Ethanolamide formula | (±)19(20)-EDP Ethanolamide molecular weight